Brief Title
Neuropsychological Evaluation for Early Diagnosis of PSP
Official Title
The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy
Brief Summary
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.
Detailed Description
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.
Study Type
Observational
Primary Outcome
MMSE
Secondary Outcome
6MWT
Condition
Progressive Supranuclear Palsy
Intervention
Cognitive evaluation
Study Arms / Comparison Groups
PSP patients
Description: Patients suffering from Progressive Supranuclear Palsy (PSP)
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Behavioral
Estimated Enrollment
112
Start Date
January 1, 2016
Completion Date
March 2, 2018
Primary Completion Date
March 1, 2018
Eligibility Criteria
Inclusion Criteria: - Patients fulfilling the criteria for idiopathic PD - Patients fulfilling the criteria for PSP Exclusion Criteria: - Any other neurodegenerative disorders or medical conditions different from PD / PSP
Gender
All
Ages
N/A - N/A
Contacts
Giuseppe Frazzitta, MD, ,
Administrative Informations
NCT ID
NCT03478124
Organization ID
NPsy-PSP
Responsible Party
Sponsor
Study Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini
Study Sponsor
Giuseppe Frazzitta, MD, Principal Investigator, Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, "Moriggia-Pelascini" Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy
Verification Date
March 2018